FibroGen (FGEN)
(Delayed Data from NSDQ)
$1.04 USD
+0.02 (1.96%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
FGEN 1.04 +0.02(1.96%)
Will FGEN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FGEN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FGEN
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
FGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
Other News for FGEN
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
Kind Pharmaceutials announces settlement agreement with FibroGen
ACB, BRNS and EDUC among mid-day movers
12 Health Care Stocks Moving In Wednesday's Intraday Session
Commit To Buy FibroGen At $1, Earn 44.2% Annualized Using Options